Latest news
Shionogi (TSE:4507) Starts U.S. XOCOVA Sales As Strong Q1 Results Put Valuation In Focus - simplywall.stsimplywall.st · Fri, 07 Aug 2026 02:57:07 GMT【Shionogi (4507.T) FY2026 Q1 Earnings Call】Revenue Hits Record ¥163.3 Billion, All Profit Lines at All-Time Highs — ViiV Equity Method and U.S. Business Drive Growth, PPA Incomplete Raises Questions on Zero Amortization Disclosure - finance.biggo.comfinance.biggo.com · Tue, 04 Aug 2026 08:55:00 GMTOral Antiviral Xocova Available for COVID-19 Postexposure Prophylaxis - Endocrinology AdvisorEndocrinology Advisor · Fri, 31 Jul 2026 04:00:00 GMTShionogi (TSE:4507) Is Up 6.5% After U.S. Launch Of XOCOVA COVID Prophylaxis Drug – Has The Bull Case Changed? - simplywall.stsimplywall.st · Thu, 30 Jul 2026 08:36:24 GMTShionogi makes the call on COVID pill Xocova TV spot - Fierce PharmaFierce Pharma · Thu, 30 Jul 2026 07:00:00 GMTShionogi’s Xocova now available in USA - The Pharma LetterThe Pharma Letter · Wed, 29 Jul 2026 12:23:39 GMT(ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure* - Business WireBusiness Wire · Tue, 28 Jul 2026 12:30:00 GMT